Therefore, this study aimed to explore the possible prognostic significance of aberrant promoter hypermethylation of RASSF1A, which has been found frequently in neuroblastoma tumours, using pretherapeutic serum of neuroblastoma patients as a surrogate marker for circulating tumour cells. The gene discussed is RASSF1; the disease is neoplasm.